Juvista (Avotermin) in Breast Reduction Surgery Scars
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Severe scarring is a common problem following breast reduction surgery, studies have shown
that over 64% of patients develop a hypertrophic scar at three months after the operation.
Scar severity can be influenced by a large number of factors including age, sex, skin
thickness and tension, ethnicity and the position of the scar on the body. Therefore the most
sensitive and reliable method to assess the efficacy of an anti-scarring treatment is to
compare bilateral wounds on the same individual. Bilateral breast reduction surgery provides
an ideal model for a within patient evaluation of anti-scarring activity in wounds which
develop into bad scars.
This study is being undertaken to investigate the efficacy and safety of Juvista (given as an
intradermal injection of 200ng per 1cm wound margin) in the reduction of scar appearance
applied to approximated wound margins following bilateral reduction mammaplasty.